Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-062146
Filing Date
2025-05-01
Accepted
2025-05-01 18:31:59
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 40778
  Complete submission text file 0000950170-25-062146.txt   42636
Mailing Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453 (781) 312-3013
Jade Biosciences, Inc. (Subject) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-92668 | Film No.: 25904924
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

EIN.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D